<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00091195</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01036</org_study_id>
    <secondary_id>CCCWFU 83403</secondary_id>
    <secondary_id>U10CA081851</secondary_id>
    <nct_id>NCT00091195</nct_id>
    <nct_alias>NCT01645670</nct_alias>
    <nct_alias>NCT01660282</nct_alias>
  </id_info>
  <brief_title>Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer</brief_title>
  <official_title>A Phase II Study Of Single Agent Depsipeptide (FK228) In Recurrent, Platinum Sensitive Adeno-Carcinoma Of The Ovary Or Peritoneum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well depsipeptide (romidepsin) works in treating patients&#xD;
      with recurrent ovarian epithelial or peritoneal cavity cancer. Drugs used in chemotherapy,&#xD;
      such as depsipeptide (romidepsin), work in different ways to stop tumor cells from dividing&#xD;
      so they stop growing or die. Depsipeptide (romidepsin) may also stop the growth of ovarian&#xD;
      epithelial or peritoneal cavity cancer by stopping blood flow to the tumor and by blocking&#xD;
      the enzymes necessary for their growth&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the response rate of recurrent, platinum-sensitive adenocarcinoma of the&#xD;
      ovarian or peritoneal to depsipeptide (romidepsin).&#xD;
&#xD;
      II. To determine the toxicity of depsipeptide in this patient population.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive depsipeptide (romidepsin) intravenously (IV) over 4 hours on days 1, 8, and&#xD;
      15. Courses repeat every 28 days in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Patients are followed up for 5 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Administratively complete.&#xD;
  </why_stopped>
  <start_date>September 2004</start_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Estimated as proportion of patients with complete or partial reduction in tumor burden.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity as assessed by CTCAE version 3.0</measure>
    <time_frame>Up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to progression</measure>
    <time_frame>From first treatment until the date of progression, assessed up to 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>From first treatment until death or the last date of contact, assessed up to 5 years</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Primary Peritoneal Cavity Cancer</condition>
  <condition>Recurrent Ovarian Epithelial Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (single-agent depsipeptide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive depsipeptide (romidepsin) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>romidepsin</intervention_name>
    <arm_group_label>Treatment (single-agent depsipeptide)</arm_group_label>
    <other_name>FK228</other_name>
    <other_name>FR901228</other_name>
    <other_name>Istodax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed primary ovarian epithelial or peritoneal&#xD;
             cavity cancer&#xD;
&#xD;
               -  Histologic confirmation of recurrent disease not required&#xD;
&#xD;
          -  Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by&#xD;
             conventional techniques (including palpation, plain x-ray, computed tomography [CT]&#xD;
             scan, or magnetic resonance imaging [MRI]) OR ≥ 10 mm by spiral CT scan&#xD;
&#xD;
          -  Achieved a complete response after initial prior platinum-containing (cisplatin or&#xD;
             carboplatin) chemotherapy regimen (e.g., conventional-dose therapy, high-dose therapy,&#xD;
             consolidation therapy, or extended therapy after surgical or nonsurgical assessment)&#xD;
&#xD;
               -  Patients who have not received paclitaxel or docetaxel as initial therapy may&#xD;
                  receive a second regimen containing these drugs&#xD;
&#xD;
               -  No prior chemotherapy for persistent or recurrent disease, including re-treatment&#xD;
                  with the original regimen&#xD;
&#xD;
          -  Platinum-sensitive disease, defined as having a treatment-free interval with no&#xD;
             evidence of progressive disease for &gt; 6 but &lt; 12 months after completion of a&#xD;
             platinum-based regimen&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
          -  Performance status - Eastern Cooperative Oncology Group (ECOG) 0-2&#xD;
&#xD;
          -  Performance status - Karnofsky 60-100%&#xD;
&#xD;
          -  More than 6 months&#xD;
&#xD;
          -  White blood cells (WBC) ≥ 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times upper&#xD;
             limit of normal (ULN)&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  No New York Heart Association class III or IV congestive heart failure&#xD;
&#xD;
          -  No myocardial infarction within the past year&#xD;
&#xD;
          -  No uncontrolled dysrhythmias&#xD;
&#xD;
          -  No poorly controlled angina&#xD;
&#xD;
          -  No history of serious ventricular arrhythmia (e.g., ventricular tachycardia or&#xD;
             ventricular fibrillation, ≥ 3 beats in a row)&#xD;
&#xD;
          -  QTc interval &lt; 500 msec&#xD;
&#xD;
          -  No other significant cardiac disease&#xD;
&#xD;
          -  Potassium normal&#xD;
&#xD;
          -  Magnesium normal&#xD;
&#xD;
          -  No uncontrolled electrolyte abnormality (hypokalemia and hypomagnesemia)&#xD;
&#xD;
          -  No ongoing or active infection requiring antibiotics&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biological composition to study drug&#xD;
&#xD;
          -  No neuropathy ≥ grade 2&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other invasive malignancy within the past 5 years except nonmelanoma skin cancer&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No prior monoclonal antibodies, cytokines, or signal transduction inhibitors for&#xD;
             recurrent disease&#xD;
&#xD;
          -  No concurrent biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) for&#xD;
             the primary malignancy&#xD;
&#xD;
          -  No prior FR901228 (depsipeptide)&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior hormonal therapy for the primary malignancy&#xD;
&#xD;
          -  Concurrent estrogen replacement therapy allowed&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to &gt; 25% of bone marrow&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  More than 4 weeks since prior noncytotoxic therapy for the primary malignancy&#xD;
&#xD;
          -  No other prior noncytotoxic therapy for recurrent disease&#xD;
&#xD;
          -  No concurrent combination anti-retroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No other concurrent drugs known to have histone deacetylase inhibitor activity (e.g.,&#xD;
             valproic acid)&#xD;
&#xD;
          -  No concurrent agents that cause QTc prolongation&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer agents&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brigitte Miller</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>High Point Regional Hospital</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27261</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>September 7, 2004</study_first_submitted>
  <study_first_submitted_qc>September 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2004</study_first_posted>
  <last_update_submitted>March 18, 2013</last_update_submitted>
  <last_update_submitted_qc>March 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Romidepsin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

